Biodesix

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biodesix reports robust Q4 revenue growth and expands reimbursement coverage

Biodesix's strong revenue growth and progress in reimbursement coverage underscore its position in the lung diagnostic testing market.
Continued success with newer tests like Nodify XL2 and Nodify CDT presents opportunities for further expansion and increased payer acceptance.

Biodesix reports robust Q1 revenue growth amidst operational challenges

Biodesix's Q1 2023 performance reflects strong revenue growth driven by core lung diagnostics and test volume expansion.
While facing challenges such as increased operating expenses and delayed clinical trials, the company maintains a focus on growth.
Opportunities lie in leveraging their precision tests portfolio, revenue diversification, and strategic investments for future growth.

Biodesix reports robust Q2 earnings, eyes sustained growth trajectory

Biodesix's Q2 2023 performance reflects strong revenue growth and improved margins, driven by core lung diagnostic tests.
While facing challenges in revenue diversification and cost management, the company's focus on clinical utility and growth opportunities remains promising.
With upcoming conference presentations and investor support, Biodesix is poised to sustain growth and advance towards profitability.

Biodesix reports robust Q3 earnings and strategic growth initiatives

Biodesix delivered a strong Q3 performance with revenue growth, improved margins, and cost management.
The company faces challenges in study timelines and commercialization but has opportunities in market expansion and product development.
By focusing on sales force expansion, quality culture, and cost control, Biodesix is positioning itself for future success.
Investors should note the company's resilience, growth potential, and strategic focus on profitability and market expansion.

Biodesix reports robust 2023 performance, eyes sustained growth in 2024

Biodesix's strong 2023 performance in revenue growth and margin improvement sets the stage for sustained growth in 2024.
The company's focus on operational efficiency, market expansion, and test adoption positions it well for future success.
Challenges in sustaining growth momentum and managing costs are balanced by opportunities in market penetration and profitability.
Investments in sales expansion and ongoing clinical studies present avenues for continued growth and innovation in the coming year.

Biodesix reports robust Q1 performance, focuses on growth strategies

Biodesix's Q1 2024 performance reflects strong revenue growth and operational achievements, despite a net loss.
Strategic partnerships and financial initiatives position the company well for future growth and innovation.
Addressing profitability challenges and operational efficiency will be key for Biodesix's sustained success in the competitive healthcare market.

Biodesix reports robust Q2 growth, raises revenue guidance for 2024

Biodesix's Q2 2024 performance reflects strong revenue growth and operational improvements, despite some profitability challenges.
The company's focus on innovation in lung cancer care and positive workplace culture position it well for future success.
With increased revenue guidance, expanding market opportunities, and a commitment to impact healthcare, Biodesix shows promise for continued growth.

Biodesix reports robust Q3 performance amidst revenue growth challenges

Biodesix demonstrated strong financial performance in Q3 2024 with revenue growth, improved margins, and a focus on innovation.
While facing challenges in biopharma services revenue and operational disruptions, the company remains resilient and proactive.
Opportunities lie in revenue growth through lung volume increase, addressing payment issues, and expanding sales team effectiveness.
Overall, Biodesix's strategic focus on growth and efficiency positions it well for future success in the diagnostics market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2023 International Conference. The meeting will take place May 19-24, 2023, in Washington, DC. Data from the abstract titled, Assessmen.

Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

Biodesix, Inc. (NASDAQ:BDSX ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Alex Vukasin - Canaccord Genuity Operator Good day, and thank you for standing by and welcome to the Biodesix First Quarter 2023 Earnings Conference Call. At this time all participants are in a listen-only mode.

Biodesix, Inc. (BDSX) Q1 2023 Earnings Call Transcript

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the first quarter ended March 31, 2023 and provided a corporate update. “Throughout the quarter we continued to make excellent progress and I am pleased with the start to the year. Looking at our financial performance, we reported total revenue of $9.1 million for the first quarter 2023, which rep.

Biodesix Announces First Quarter 2023 Results and Highlights

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for first quarter ended March 31, 2023 after the close of trading on Thursday, May 11. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webca.

Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023

Biodesix, Inc. (NASDAQ:BDSX ) Q4 2022 Earnings Conference Call March 6, 2023 8:00 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Andrew Brackmann - William Blair Operator Good day, and thank you for standing by. Welcome to the Biodesix Fourth Quarter and Year-End 2022 Earnings Conference Call.

Biodesix, Inc. (BDSX) Q4 2022 Earnings Call Transcript

Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -7.69% and 10.23%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Biodesix, Inc. (BDSX) Reports Q4 Loss, Misses Revenue Estimates

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the fourth quarter and year ended December 31, 2022 (fiscal 2022) and provided a corporate update. “It has been a productive year for Biodesix, and I am extremely proud of our team's performance.

Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will participate in a fireside chat and host in-person 1x1 investor meetings at Cowen's 43rd Annual Healthcare Conference being held from March 6-8, 2023.

Biodesix to Participate at Cowen's 43rd Annual Healthcare Conference

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2022 before the open of trading on Monday, March 6. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:00 a.m. Eastern Time on the same day.

Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

Biodesix, Inc. published its Q3 financial results on November 3, 2022. The firm provides an array of lung cancer diagnostic tests in the U.S.

Biodesix Appears Poised For 2023 Growth

BOULDER, Colo.--( BUSINESS WIRE )--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced positive coverage decisions from four private payers including Blue Cross Blue Shield of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shield of Kansas City, and Capital District Physician's Health Plan (CDPHP) of New York, all effective fourth quarter 2022. Biodesix's Nodify XL2® test will now be covered for more than 2.3 million enrollees of Blue Cross of North Carolina, 1.2 million enrollees of Blue Cross Blue Shield of South Carolina, 0.5 million enrollees from Blue Cross Blue Shield of Kansas City, and 0.4 million enrollees of CDPHP across New York State.

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test

BOULDER, Colo.--( BUSINESS WIRE )--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry.

Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

BOULDER, Colo.--( BUSINESS WIRE )--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the Company was named the leading Proteomics Solutions Company in the U.S. by Life Sciences Review Magazine , featured in the December 2022 issue, “Top 10 Proteomics Solutions Companies of 2022.” Biodesix is a market leader with over 15 years of experience in the field of clinical proteomics. The Company's expertise focuses on profiling the patient's immune response to their cancer with blood-based proteomic solutions, in addition to genomic insights. Biodesix's core technologies and extensive machine learning and transparent AI expertise allow for identifying clinically relevant proteomic differences in patient populations to help guide treatment strategy. To date, Biodesix has performed over 125,000 proteomic tests for research and clinical use.

Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine

BOULDER, Colo.--( BUSINESS WIRE )--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the closing of its underwritten public offering of 35,075,000 shares of its common stock at a price to the public of $1.15 per share, including the exercise in full by the underwriter of its option to purchase up to an additional 4,575,000 shares of common stock in the offering. The gross proceeds to Biodesix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Biodesix, were $40.3 million.

Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

BOULDER, Colo.--( BUSINESS WIRE )--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the public of $1.15 per share, before underwriting discounts and commissions. The gross proceeds to Biodesix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Biodesix, are expected to be $35.1 million. The offering is expected to close on November 21, 2022, subject to customary closing conditions. Additionally, Biodesix has granted the underwriters a 30-day option to purchase up to an additional 4,575,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering will be sold by Biodesix.

Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock

BOULDER, Colo.--( BUSINESS WIRE )--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it has commenced an underwritten public offering of $30 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. In connection with the offering, Biodesix intends to grant the underwriters a 30-day option to purchase up to an additional $4.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are to be sold by Biodesix. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Biodesix Announces Proposed Public Offering of Common Stock

BOULDER, Colo.--( BUSINESS WIRE )--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it has obtained a term loan facility for up to $50 million from Perceptive Advisors, a leading healthcare investment firm focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. This debt capital, which is conditioned on the Company raising at least $30 million in gross proceeds through sale of its equity securities, is part of a strategic fundraising effort to strengthen the Company's balance sheet, reduce near term cash use and enable the continued growth trajectory of the core lung diagnostics business. The proceeds from this debt offering will be used for repayment of existing debt facilities, working capital, and general corporate purposes, including expansion of the commercialization activities for the Company's five Medicare reimbursed lung diagnostic tests.

Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million

Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Biodesix, Inc. (NASDAQ:BDSX ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Representatives Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Chris Brinzey - Investor Relations Conference Call Participants Andrew Brackmann - William Blair Max Masucci - Cowen & Company Kyle Mikson - Canaccord Genuine Operator Good day! And thank you for standing by.

Biodesix, Inc. (BDSX) Q3 2022 Earnings Call Transcript

Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -6.25% and 1.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates

Biodesix Announces Third Quarter 2022 Results and Highlights

Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022

Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions

Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (NASDAQ: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Company expects to report third quarter 2022 total revenue to be in the range of $10.6 million to $11.2 million, representing growth of 62% to 71% over the third quarter 2021. The strength in the third quarter 2022 total revenue reflects continued growth in the Company's core lung diagnostic testing. The financial results inclu

News for Biodesix Stock (BDSX)